146 related articles for article (PubMed ID: 19475723)
41. Tolerability and efficacy of oral loading of levetiracetam.
Koubeissi MZ; Amina S; Pita I; Bergey GK; Werz MA
Neurology; 2008 May; 70(22 Pt 2):2166-70. PubMed ID: 18505995
[TBL] [Abstract][Full Text] [Related]
42. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.
Chung S; Ceja H; Gawłowicz J; Avakyan G; McShea C; Schiemann J; Lu S
Epilepsy Res; 2012 Aug; 101(1-2):92-102. PubMed ID: 22516508
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of levetiracetam as adjunctive therapy in Japanese patients with uncontrolled partial-onset seizures.
Inoue Y; Yagi K; Ikeda A; Sasagawa M; Ishida S; Suzuki A; Yoshida K;
Psychiatry Clin Neurosci; 2015 Oct; 69(10):640-8. PubMed ID: 25854635
[TBL] [Abstract][Full Text] [Related]
44. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
46. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study.
Striano P; Coppola A; Vacca G; Zara F; Brescia Morra V; Orefice G; Striano S
J Neurol; 2006 Jun; 253(6):762-6. PubMed ID: 16683063
[TBL] [Abstract][Full Text] [Related]
47. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
48. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures.
Zhou B; Zhang Q; Tian L; Xiao J; Stefan H; Zhou D
Epilepsy Behav; 2008 Feb; 12(2):305-10. PubMed ID: 18024209
[TBL] [Abstract][Full Text] [Related]
49. A prospective analysis of the outcome of levetiracetam in clinical practice.
Nicolson A; Lewis SA; Smith DF
Neurology; 2004 Aug; 63(3):568-70. PubMed ID: 15304598
[TBL] [Abstract][Full Text] [Related]
50. Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis.
Shiue HJ; Taylor M; Sands KA
Ann Pharmacother; 2017 Oct; 51(10):862-865. PubMed ID: 28582998
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: a randomized, double-blind, noninferiority trial.
Zaccara G; Almas M; Pitman V; Knapp L; Posner H
Epilepsia; 2014 Jul; 55(7):1048-57. PubMed ID: 24902473
[TBL] [Abstract][Full Text] [Related]
52. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam.
Löscher W; Hönack D
Epilepsia; 2000 Dec; 41(12):1499-506. PubMed ID: 11114206
[TBL] [Abstract][Full Text] [Related]
53. Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project).
Consoli D; Bosco D; Postorino P; Galati F; Plastino M; Perticoni GF; Ottonello GA; Passarella B; Ricci S; Neri G; Toni D;
Cerebrovasc Dis; 2012; 34(4):282-9. PubMed ID: 23128439
[TBL] [Abstract][Full Text] [Related]
54. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.
Baulac M; Brodie MJ; Elger CE; Krakow K; Stockis A; Meyvisch P; Falter U
Epilepsia; 2007 Mar; 48(3):589-92. PubMed ID: 17326794
[TBL] [Abstract][Full Text] [Related]
55. Levetiracetam for treatment of premenstrual dysphoric disorder: a pilot, open-label study.
Kayatekin ZE; Sabo AN; Halbreich U
Arch Womens Ment Health; 2008 Jul; 11(3):207-11. PubMed ID: 18493713
[TBL] [Abstract][Full Text] [Related]
56. Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats.
Barnes Heller H; Granick M; Van Hesteren M; Boothe DM
J Vet Intern Med; 2018 May; 32(3):1145-1148. PubMed ID: 29671898
[TBL] [Abstract][Full Text] [Related]
57. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers.
Levy RH; Ragueneau-Majlessi I; Baltes E
Epilepsy Res; 2001 Aug; 46(2):93-9. PubMed ID: 11463510
[TBL] [Abstract][Full Text] [Related]
58. An open-label study of levetiracetam for the treatment of social anxiety disorder.
Simon NM; Worthington JJ; Doyle AC; Hoge EA; Kinrys G; Fischmann D; Link N; Pollack MH
J Clin Psychiatry; 2004 Sep; 65(9):1219-22. PubMed ID: 15367048
[TBL] [Abstract][Full Text] [Related]
59. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
Betts T; Waegemans T; Crawford P
Seizure; 2000 Mar; 9(2):80-7. PubMed ID: 10845730
[TBL] [Abstract][Full Text] [Related]
60. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.
Ferrendelli JA; French J; Leppik I; Morrell MJ; Herbeuval A; Han J; Magnus L
Epilepsy Behav; 2003 Dec; 4(6):702-9. PubMed ID: 14698704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
